Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines

Cancer Research

Volumn 57, Issue 5, 1997, Pages 850-856

  Johnson, Steven W ^a   Laub, Paul B ^a   Beesley, Jacqueline S ^a   Ozols, Robert F ^a   Hamilton, Thomas C ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; GLUTATHIONE; MITOMYCIN C; PACLITAXEL;

ARTICLE; CANCER; CANCER RESISTANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA ADDUCT; DNA DAMAGE; DNA DRUG COMPLEX; DNA REPAIR; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CISPLATIN; DNA DAMAGE; DNA REPAIR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE; ETOPOSIDE; FEMALE; GLUTATHIONE; HUMANS; MITOMYCIN; OVARIAN NEOPLASMS; PACLITAXEL; REGRESSION ANALYSIS; TUMOR CELLS, CULTURED;

EID: 0031020450     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Ozols, R. F. Ovarian cancer. Part II. Treatment. Curr. Prob. Cancer. 16: 63-126, 1992.
2. Reedijk, J. The mechanism of action of platinum anti-tumor drugs. Pure Appl. Chem., 59: 181-192, 1987.
3. Godwin, A. K., Meister, A., O'Dwyer, P. J., Huung, C. S., Hamilton, T. C., and Anderson, M. E. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl. Acad, Sci. USA, 89: 3070-3074, 1992.
4. Hamaguchi, K., Godwin, A. K., Yakushiji, M., O'Dwyer, P. J., Ozols, R. F., and Hamilton, T. C. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res., 53: 5225-5232, 1993.
5. Johnson, S. W., Perez, R. P., Godwin, A. K., Yeung, A. T., Handel, L. M., Ozols, R. F., and Hamilton, T. C. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem. Pharmacol., 47: 689-697, 1994.
6. Johnson, S. W., Swiggard, P. A., Handel, L. M., Brennan, J. M., Godwin, A. K., Ozols, R. F., and Hamilton, T. C. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and - resistant human ovarian cancer cells. Cancer Res., 54: 5911-5916, 1994.
7. Hansen, M. B., Nielsen, S. E., and Berg, K. J. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. Immunol. Methods, 119: 203-210, 1989.
8. Griffith, O. W. Determination of glututhione and glutathione disulfide using glutathione reductase and 2-vinyl pyridine. Anal. Biochem., 106: 207-212, 1980.
9. Iles. T. C. Multiple regression. In: J. C Fry (ed.). Biological Data Analysis: A Practical Approach, pp, 127-172. New York: Oxford University Press, 1993.
10. Lopes, N. M., Adams, E. G., Pitts, T. W., and Bhuyan, B. K. Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother. Pharmacol., 32: 235-242, 1993.
11. Dawson-Saunders, B., and Trapp, R. G. Basic and Clinical Biostatistics, Ed. 2, pp. 167-169, Norwalk, CT: Appleton and Lange, 1994.
12. Perez, R. P., Hamilton, T. C., and Ozols, R. F. Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems. Pharmacol. Ther., 48: 19-27, 1990.
13. Hromas, R. A., North, J. A., and Burns, C. P. Decreased cisplatin uptake by resistant L1210 leukemia cells. Cancer Lett., 36: 197-201, 1987.
14. Waud, W. R. Differential uptake of cis-diamminedichloroplatinum(II) by sensitive and resistant murine L1210 leukemia cells. Cancer Res., 47: 6549-6555, 1987.
15. Richon, V. M., Schulte, N., and Eastman, A. Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II). Cancer Res., 47: 2056-2061, 1987.
16. Teicher, B. A., Holden, S. A., Kelley, M. J., Shea, T. C., Cucchi, C. A., Rosowsky, A., Henner, W. D., and Frei, E., III. Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res., 47: 388-393, 1987.
17. Andrews, P. A., Velury, S., Mann, S. C., and Howell, S. B. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res., 48: 68-73, 1988.
18. Kraker, A. J., and Moore, C. W. Accumulation of cis-diamminedichloroplatinum(II) and platinum analogues by platinum-resistant murine leukemia cells in vitro. Cancer Res., 48: 9-13, 1988.
19. Kuppen, P. J. K., Schuitemaker, H., van't Veer, L. J., de Bruijn, E. A., van Oosterom, A. T., and Schrier, P. I. cis-Diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines. Cancer Res., 48: 3355-3359, 1988.
20. Kelland, L. R., Mistry, P., Abel, G., Loh, S. Y., O'Neill, C. F., Murrer, B. A., and Harrap, K. R. Mechanism-related circumvention of acquired cis-diamminedichloro- platinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum IV dicarboxylates. Cancer Res., 52: 3857-3864, 1992.
21. Johnson, S. W., Shen, D-W., Pastan, I., Gottesman, M. M., and Hamilton, T. C. Cross-resistance, cisplatin accumulation and platinum-DNA adduct formation and removal in cisplatin-sensitive and -resistant human hepatoma cell lines. Exp. Cell Res., 226: 133-139, 1996.
22. Gately, D. P., and Howell, S. B. Cellular accumulation of the anticancer agent cisplatin: a review. Br. J. Cancer. 67: 1171-1175, 1993.
23. Ishikawa, T., and Ali-Osman, F. Glutathione-associated cis-diarnminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. J. Biol. Chem., 268: 20116-20125, 1993.
24. Mistry, P., Loh, S. Y., Kelland, L. R., and Harrap, K. R. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian carcinoma cell lines. Int. J. Cancer, 55: 848-856, 1993.
25. Hosking, L. K., Whelan, R. D. H., Shellard, S. A., Bedford, P., and Hill, B. T. An evaluation of the role of glutathione and its associated enzymes in the expression of differential sensitivities to antitumor agents shown by a range of human tumour cell lines. Biochem. Pharmacol., 40: 1833-1842, 1990.
26. Hrubisko, M., McGown, A. T., and Fox, B. W. The role of metallothionein. glutathione, glutathione S-transferases and DNA repair in resistance to platinum drugs in a series of L1210 cell lines made resistant to anticancer platinum agents. Biochem. Pharmacol., 45: 253-256, 1993.
27. Mistry, P., Kelland, L. R., Abel, G., Sidhar, S., and Harrap, K. R. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br. J. Cancer. 64: 215-220, 1991.
28. Pendyala, L., Creaven, P. J., Ferez, R., Zdanowicz, J. R., and Raghavan, D. Intracellular glutathione and cytotoxicity of platinum complexes. Cancer Chemother. Pharmacol., 36: 271-278, 1995.
29. Masuda, H., Ozols, R. F., Lai, G-M., Fojo, A., Rothenberg, M., and Hamilton, T. C. Increased DNA repair as a mechanism of acquired resistance to cis-diamrninedichloroplatinum(II) in human ovarian cancer cell lines. Cancer Res., 48: 5713-5716, 1988.
30. Lai, G-M., Ozols, R. F., Smyth, J. F., Young, R. C., and Hamilton, T. C. Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochem. Pharmacol., 37: 4597-4600, 1988.
31. Eastman, A., and Schulte, N. Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry, 27: 4730-4734, 1988.
32. Masuda, H., Tanaka, T., Matsuda, H., and Kusaba, I. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res., 50: 1863-1866, 1990.
33. Parker, R. J., Eastman, A., Bostick-Bruton, F., and Reed, E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J. Clin. Invest., 87: 772-777, 1991.
34. Zhcn, W., Link, C. J., Jr., O'Connor, P. M., Reed, E., Parker, P., Howell, S. B., and Bohr. V. A. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol. Cell. Biol., 12: 3689-3698, 1992.
35. Wood, R. D. Studying nucleotide excision repair of mammalian DNA in a cell-free system. Ann. NY Acad. Sci., 726: 274-280, 1994.
36. Hill, B. T., Shellard, S. A., Hosking, L. K., Fichtinger-Schepman, A. M. J., and Bedford, P. Enhanced DNA repair and tolerance of DNA damage associated with resistance to cis-diammine-dichloroplatinum(II) after in vitro exposure of a human teratoma cell line to fractionated X-irradiation. Int. J. Radiat. Oncol. Biol. Phys., 19: 75-83, 1990.
37. Kaufmann, W. K. Pathways of human cell post-replication repair. Carcinogenesis (Lond.), 10: 1-11, 1989.
38. Mamenta, E. L., Poma, E. E., Kaufmann, W. K., Delmastro, D. A., Grady, H. L., and Chancy, S. G. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res., 54: 3500-3505, 1994.
39. Hoffmann, J-S., Pillaire, M-J., Maga, G., Podust, V., Hubscher, U., and Villani, G. DNA polymerase B bypasses in vitro a single d(GpG)-cisplatin adduct placed on codon 13 of the HRAS gene. Proc. Natl. Acad. Sci. USA, 92: 5356-5360, 1995.
40. 2 phase and cell death induced by cisplatin. J. Natl. Cancer Inst., 52: 749-755, 1990.
41. O'Connor, P. M., Ferris, D. K., Hoffmann, I., Jackman, J., Draetta, G., and Kohn, K. W. Role of the cdc25C phosphatase in G2 arrest induced by nitrogen mustard. Proc. Natl. Acad. Sci. USA, 91: 9480-9484, 1994.
42. Demarcq, C., Bunch, R. T., Creswell, D., and Eastman, A. The role of cell cycle progression in cisplatin-induced apoptosis in Chinese hamster ovary cells. Cell Growth & Differ., 5: 983-993, 1994.
43. Segal-Bendirdjian, E., and Jacquemin-Sablon, A. Cisplatin resistance in a murine leukemia cell line is associated with a detective apoptotic process. Exp. Cell Res., 218: 201-212, 1995.
44. Miyashita, T., and Reed, J. C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood, 81: 151-157, 1993.
45. Minn, A. J., Rudin, C. M., Boise, L. H., and Thompson, C. B. Expression of Bcl-XL can confer a multidrug resistant phenotype. Blood, 86: 1903-1910, 1995.
46. Sklar, M. D. Increased resistance to cis-diamminedichloroplatinum(II) in NIH 3T3 cells transformed by ras oncogenes. Cancer Res., 48: 793-797, 1988.
47. Isonishi, S., Horn, D. K., Thiebaut, F. B., Mann, S. C., Andrews, P. A., Basu, A., Lazo, J. S., Eastman, A., and Howell, S. B. Expression of the c-Ha-Ras oncogene induces resistance to cisplatin. Cancer Res., 57: 5903-5905, 1991.
48. Chapman, R. S., Whetton, A. D., Chresta, C. M., and Dive, C. Characterization of drug resistance mediated via the suppression of apoptosis by Abelson protein tyrosine kinase. Mol. Pharmacol., 48: 334-343, 1995.
49. Benz, C. C., Scott, G. K., Sarup, J. C., Johnson, R. M., Tripathy, D., Coronado, E., Shepard, H. M., and Osborne, C. K. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat., 24: 85-95, 1992.
50. Eliopoulos, A. G., Kerr, D. J., Herod, J., Hodgkins, L., Krajewski, S., Reed, J. C., and Young, L. S. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene, 11: 1217-1228, 1995.